Oncology - Physician's Channel - Mount Sinai New York

Skip to main content

Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Mount Sinai Tisch Cancer Center—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.

Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's Department of Oncology is nationally ranked by U.S. News & World Report.

Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Mount Sinai Tisch Cancer Center—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.

Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's Department of Oncology is nationally ranked by U.S. News & World Report.

Refer a Patient Online

Or call 212-241-4983

Find A Specialist

Latest Content |view more

Ramon Parsons, MD, PhD, explains PTEN and cancer

Ramon Parsons, MD, PhD, explains PTEN and cancer

A Department of Medicine Grand Rounds presented by Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute, and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai

Luis M. Isola, MD, discusses fighting hematological cancers

Luis M. Isola, MD, discusses fighting hematological cancers

A profile of Luis M. Isola, MD, Director of Cancer Clinical Programs, Mount Sinai Health System

Nina Bhardwaj, MD, PhD, was Honored with the 2022 ESMO Award for Immuno-Oncology From the European Society for Medical Oncology

Nina Bhardwaj, MD, PhD, was Honored with the 2022 ESMO Award for Immuno-Oncology From the European Society for Medical Oncology

Nina Bhardwaj, MD, PhD, was honored with the 2022 ESMO Award for Immuno-Oncology from the European Society for Medical Oncology in recognition of her outstanding contributions to cancer immunology research.

Clinical Trials for Challenging Cancer Cases at The Tisch Cancer Institute at Mount Sinai

Clinical Trials for Challenging Cancer Cases at The Tisch Cancer Institute at Mount Sinai

The Tisch Cancer Institute (TCI) offers a robust portfolio of clinical trials that span multiple cancers.

Researchers Discover a Mutated Gene That Triggers More Aggressive Melanoma

Researchers Discover a Mutated Gene That Triggers More Aggressive Melanoma

The effects of ARID2 gene mutations are being explored for the first time in advanced melanoma, which not only sheds light on how those tumor cells become more aggressive, but also opens doors to better treatment and prevention strategies in the future.

Breaking New Ground With Blood Cancers Through the Lens of Splicing Factor Mutations

Breaking New Ground With Blood Cancers Through the Lens of Splicing Factor Mutations

Recent work with induced pluripotent stem cells has helped uncover complex mechanisms in myelodysplastic syndrome and acute myeloid leukemia for the first time. This discovery could pave the way for improving current treatments, or even for finding new ones.

Latest Study on World Trade Center Cancer Suggests Epigenetic Changes in Prostate Tissue

Latest Study on World Trade Center Cancer Suggests Epigenetic Changes in Prostate Tissue

The World Trade Center (WTC) Health Program at Mount Sinai has characterized differences in prostate cancer risk between that of responders to the attack and that of the general public.

Tisch Cancer Institute: New Faculty Spotlight

Tisch Cancer Institute: New Faculty Spotlight

The Tisch Cancer Institute continues to benefit from the addition of topflight investigators to its diverse research team from medical centers and laboratories around the world.

TCI Pioneers in Targeted Protein Degradation For Cancers Considered Undruggable

TCI Pioneers in Targeted Protein Degradation For Cancers Considered Undruggable

Jian Jin, PhD, continues to push frontiers in oncology research at The Tisch Cancer Institute (TCI), with his latest discoveries including advances in protein degradation in breast cancer and leukemia.

A Colorful New Approach to Identifying Regulators of the Tumor Microenvironment

A Colorful New Approach to Identifying Regulators of the Tumor Microenvironment

Traditionally, identifying the genetic components of a tumor microenvironment had been laborious and time-consuming.

TCI Programs Take Cancer Care and Research to a New Era

TCI Programs Take Cancer Care and Research to a New Era

The Tisch Cancer Institute (TCI) is undertaking the herculean task of speeding up the time it takes for experimental therapeutics to reach patients.

Immunoediting Allows for Long-Term Survival Of Pancreatic Cancer Patients

Immunoediting Allows for Long-Term Survival Of Pancreatic Cancer Patients

A recent study in pancreatic cancer provided evidence for immunoediting in human cancers, opening up the potential for cancer vaccines that could improve survival and outcomes.

Making Investigative Inroads Against One of the Most Elusive Forms of Cancer

Making Investigative Inroads Against One of the Most Elusive Forms of Cancer

Understanding of a rare bile duct cancer enters a new era as Mount Sinai researchers delve into its tumor microenvironment and progression.

The Tisch Cancer Institute 2023 Specialty Report

The Tisch Cancer Institute 2023 Specialty Report

At The Tisch Cancer Institute, we are investigating the complexities of cancer biology and behavior with the goal of improving the lives of those affected by cancer and minimizing its power.

Mount Sinai Researcher Receives Prestigious Award From the Asbestos Disease Awareness Organization

Mount Sinai Researcher Receives Prestigious Award From the Asbestos Disease Awareness Organization

Andrea Wolf, MD, Director of the New York Mesothelioma Program at the Mount Sinai Health System, has received the prestigious 2022 Irving J. Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization.

Ropeginterferon (BESREMI) for Polycytheia Vera

Ropeginterferon (BESREMI) for Polycytheia Vera

John Mascarenhas, MD, discusses findings from the ECLIPSE study.

Lung Cancer Screening Dramatically Increases Long-term Survival Rate

Lung Cancer Screening Dramatically Increases Long-term Survival Rate

Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves the survival rate of cancer patients over a 20-year period.

Modifications to Ivor Lewis Esophagectomy Improve Outcomes

Modifications to Ivor Lewis Esophagectomy Improve Outcomes

Raja M. Flores, MD, and Brian Housman, MD, have pioneered major modifications to the Ivor Lewis esophagectomy that make it less invasive and enable patients to recover more quickly.

Mount Sinai Children’s Brain and Spinal Tumor Center: A Race to Cure Childhood Brain Cancer

Mount Sinai Children’s Brain and Spinal Tumor Center: A Race to Cure Childhood Brain Cancer

Three leaders in childhood brain cancer awarded a series of generous grants for research.

Mount Sinai Study Identifies New Gene That Drives Colon Cancer

Mount Sinai Study Identifies New Gene That Drives Colon Cancer

Researchers at Mount Sinai’s Tisch Cancer Institute have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor cells.

Scientists Identify Unique Breast Cancer Cells That Control Their Ability to Proliferate and Colonize the Lungs

Scientists Identify Unique Breast Cancer Cells That Control Their Ability to Proliferate and Colonize the Lungs

For the first time, scientists have identified a type of cancer cell in triple negative breast tumors, which is highly efficient in invading and colonizing distant organs but slow their growth upon colonization.

Mount Sinai Researchers Find Spaceflight May Be Associated With DNA Mutations and Increased Risk of Developing Heart Disease and Cancer

Mount Sinai Researchers Find Spaceflight May Be Associated With DNA Mutations and Increased Risk of Developing Heart Disease and Cancer

Mount Sinai study could lead to ongoing health monitoring of astronauts to assess possible health risks and prevent disease progression.

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking ...

Mount Sinai Cardio-Oncology Program Receives Highest Designation for Excellence

Mount Sinai Cardio-Oncology Program Receives Highest Designation for Excellence

The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...

Institutional Perspective in Cancer – GI: Chaired by Deirdre Cohen, MD

Institutional Perspective in Cancer – GI: Chaired by Deirdre Cohen, MD

This session on cancers of the GI tract, hosted by OncLive, provides an update on how Mount Sinai is treating patients with the most current therapies

Mount Sinai Study finds Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

Mount Sinai Study finds Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates

Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle...

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure for Myerlofibrosis: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure for Myerlofibrosis: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Improvement in spleen and symptom burden with fedratinib therapy for patients with myelofibrosis

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued ...

Mount Sinai Scientists discover gene mutation that signals aggressive melanoma

Mount Sinai Scientists discover gene mutation that signals aggressive melanoma

Emily Bernstein, PhD, discusses the study discovering gene mutation that signals aggressive melanoma.

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

A subset of blood cancer patients still remained vulnerable, needing fourth dose or antibody treatments

Lung Scans Reveal Elevated Incidence of Liver Disease Among 9/11 First Responders

Lung Scans Reveal Elevated Incidence of Liver Disease Among 9/11 First Responders

World Trade Center (WTC) first responders who underwent low-dose CT (computed tomography) lung screenings were three times more likely to have moderate-to-severe steatosis than others, a result much higher than expected.

Deciphering the Mechanism of Resistance to CDK4/6 Inhibitors in Multiple Tumor Types

Deciphering the Mechanism of Resistance to CDK4/6 Inhibitors in Multiple Tumor Types

Small-molecule inhibitors of the closely related cyclin-dependent kinases 4 and 6 (CDK4/6 is) that have shown success in treating patients with metastatic breast cancer have been only modestly effective against other tumor types.

A Novel Target for Treating Early Stage Lung Cancer

A Novel Target for Treating Early Stage Lung Cancer

Scientists led by Miriam Merad, MD, PhD, have shown for the first time that specific populations of macrophages promote tumor growth and contribute to immune evasion in early lung cancer lesions.

Identifying Lead Compounds That Effectively Treat Liver Cancer

Identifying Lead Compounds That Effectively Treat Liver Cancer

The search for effective new treatments for liver cancer has led Mount Sinai investigators to highly targeted compound libraries that include kinase inhibitors, histone modifying enzymes, and other small molecules used in combination with ...

Destroying Acute Myeloid Leukemia Cells With a Novel Antibody-Led Regimen

Destroying Acute Myeloid Leukemia Cells With a Novel Antibody-Led Regimen

Acute myeloid leukemia manages to cleverly evade the surface markers that the immune system recognizes in order to attack malignant cells.

A Promising Strategy for Preventing Cancer Metastasis and Enhancing Dormancy

A Promising Strategy for Preventing Cancer Metastasis and Enhancing Dormancy

A research team at The Tisch Cancer Institute, which focuses on the burgeoning field of cancer dormancy, has identified a promising strategy for preventing metastasis from occurring.

Improving Immunotherapy Outcomes Through "Bystander Killing"

Improving Immunotherapy Outcomes Through "Bystander Killing"

One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells lose the targeted antigen.

New Approaches to Developing Personalized Cancer Vaccines

New Approaches to Developing Personalized Cancer Vaccines

Investigators at The Tisch Cancer Institute are developing different types of personalized vaccines, including those that treat cancers with common cell mutations and those combined with checkpoint inhibitors.

Three Compounds Offer Hope in the Battle Against Mantle Cell Lymphoma

Three Compounds Offer Hope in the Battle Against Mantle Cell Lymphoma

Mount Sinai researchers led by Samir Parekh, MD, have found a family of three compounds that fit into a pocket on the SOX11 surface that interfere with DNA binding and block the mechanism by which mantle cell lymphoma develops.

Mount Sinai Gets New Chief of Pediatric Hematology-Oncology

Mount Sinai Gets New Chief of Pediatric Hematology-Oncology

Oren J. Becher, MD, was recently named Chief of the Jack Martin Division of Pediatric Hematology-Oncology, the Steven Ravitch Chair in Pediatric Hematology, and Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai.

An Engineered Molecule, MS21, Slows the Growth of Multiple Tumor Types

An Engineered Molecule, MS21, Slows the Growth of Multiple Tumor Types

Investigators Ramon Parsons, MD, PhD, and Jian Jin, PhD, have engineered a synthetic compound—a small molecule called MS21— that targets the PTEN/AKT pathway, one of the most commonly mutated pathways in human cancers.

The Adjuvant Use of Immunotherapy for Bladder Cancer

The Adjuvant Use of Immunotherapy for Bladder Cancer

The U.S. Food and Drug Administration's recent approval of the adjuvant use of nivolumab for muscle-invasive urothelial carcinoma may set a new standard of care.

Renowned Clinician Researcher Joseph A. Sparano, MD, Joins Mount Sinai

Renowned Clinician Researcher Joseph A. Sparano, MD, Joins Mount Sinai

In June 2021, clinician and researcher, Joseph A. Sparano, MD, joined The Tisch Cancer Institute as Deputy Director, where he will continue to lead clinical trials and improve treatments for breast cancer and cancers associated with HIV ...

A Message From Director Ramon Parsons, MD, PhD

A Message From Director Ramon Parsons, MD, PhD

We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries by highlighting the work of our dedicated investigators. Their advances will bring our patients better health and longevity.

Gene Signatures May Predict Outcomes Among Similar-Appearing Tumors

Gene Signatures May Predict Outcomes Among Similar-Appearing Tumors

Gene signatures derived from lung carcinoma could potentially predict outcomes among individuals with small lung cancers detected by chest CT imaging, when those tumors cannot be distinguished visually as aggressive or indolent.

Building a Hub to Catch Lung Cancer Early

Building a Hub to Catch Lung Cancer Early

Fewer than 10 percent of potentially eligible patients undergo lung cancer screening, resulting in unnecessary illness and death. The new Chief of Pulmonary, Critical Care and Sleep Medicine at Mount Sinai Morningside wants to change that.

Decline in Lung Cancer Deaths Is Linked to Increased Screening

Decline in Lung Cancer Deaths Is Linked to Increased Screening

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, a new study shows.

PD-L1 Expression: Practical Implications in Lung Cancer

PD-L1 Expression: Practical Implications in Lung Cancer

Tapping into the predictive capability of PD-L1 expression in Non-Small Cell Lung Cancer

Pursuing Progress, Precision, and Equity in Cancer Care

Pursuing Progress, Precision, and Equity in Cancer Care

With a particular focus on breast cancer, Dr. Sparano presents on progress in reducing mortality, advancing precision medicine for improved outcomes, and addressing disparities in care and outcomes.

The Tisch Cancer Institute Specialty Report 2022

The Tisch Cancer Institute Specialty Report 2022

We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries. In this report we highlight the work of our dedicated investigators who explore the complexity of cancer formation and metastasis and search for effective ways to stop it.

Mount Sinai Finds Lung Cancer Death Decline Associated With Screening, Earlier Diagnosis, and Surgery

Mount Sinai Finds Lung Cancer Death Decline Associated With Screening, Earlier Diagnosis, and Surgery

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, supporting the need for increased use of screening to save lives, according to a Mount Sinai study published in JAMA ...

Lung screening at Mount Sinai leads to early detection of lung cancer in former smoker

Lung screening at Mount Sinai leads to early detection of lung cancer in former smoker

Growing up in Austria, Wolfgang Lehner was a heavy, pack-a-day smoker from age 15 to 51. He quit smoking in 2010.

Pancreatic Cancer: Current Challenges and Future Directions

Pancreatic Cancer: Current Challenges and Future Directions

Dr. Cohen describes current challenges in the treatment of pancreatic cancer and provides evidence for emerging treatment paradigms

Researchers Identify New Drug Target for Blood Cancer, Potentially Solid Tumors

Researchers Identify New Drug Target for Blood Cancer, Potentially Solid Tumors

Findings are being used to create a clinical trial for patients with myelodysplastic syndrome

Childhood Brain Tumor Expert Named Chief of Pediatric Hematology-Oncology at Mount Sinai Kravis Children’s Hospital

Childhood Brain Tumor Expert Named Chief of Pediatric Hematology-Oncology at Mount Sinai Kravis Children’s Hospital

Dr. Becher is an expert in brain tumors in children, particularly diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain cancer. For more than a decade, his research has focused on identifying therapeutic targets to treat DIPG.

Mount Sinai Scientists Show That a Novel Therapy Could Be Effective Against Pediatric Leukemia

Mount Sinai Scientists Show That a Novel Therapy Could Be Effective Against Pediatric Leukemia

Therapy could also fight pancreatic and other cancers, researchers say

$60 million pledged to establish the Mount Sinai Tisch Cancer Center and to construct a state-of-the-art cancer hospital in Manhattan

$60 million pledged to establish the Mount Sinai Tisch Cancer Center and to construct a state-of-the-art cancer hospital in Manhattan

Cholangiocarcinoma: Bridging the Gap Between the Clinic and the Laboratory

Cholangiocarcinoma: Bridging the Gap Between the Clinic and the Laboratory

This presentation highlights the epidemiology and current management of cholangiocarcinoma, as well as future therapeutic approaches

Make a Referral

Call
212-241- 4983

Find A Specialist